Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

NCT01713725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Chronic Urticaria

Interventions

BIOLOGICAL: Omalizumab
BIOLOGICAL: Placebo

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]